Senomyx, Inc. Sends Letter to Shareholders

The Board of Directors of Senomyx, Inc. (“Senomyx” or the “Company”)
(NASDAQ: SNMX), a leading company using proprietary taste science
technologies to discover, develop, and commercialize novel flavor
ingredients and natural high intensity sweeteners for the food,
beverage, and flavor industries, today mailed a letter to shareholders
in connection with the Company’s upcoming 2017 Annual Meeting of
Shareholders to be held on May 11, 2017.

This Smart News Release features multimedia. View the full release here:

(Graphic: Business Wire)

(Graphic: Business Wire)

The full text of the letter follows:


April 20, 2017

Dear Shareholders,

At the Annual Meeting of Shareholders to be held on May 11, 2017, you
will face a critical choice that will directly impact the future of your
investment in Senomyx. You must decide whether to elect the slate of
highly-qualified and experienced Board nominees put forth by the
Company, or the slate of nominees put forth by an activist investor
group (“Concerned Shareholders and Nominees of Senomyx” or “CSNS”) that
just recently purchased less than one thousandth of one percent (0.001%)
or 300 shares of Senomyx stock.

As we have previously stressed, we believe that your investment in the
Company will be put at extreme risk should you make the decision to give
complete control of the Board to a group that owns such a miniscule
amount of Senomyx shares and that has not presented a plan for how its
members would improve the Company and lead it forward. Additionally, we
believe that the backgrounds and track records of many members of the
dissident group call into question whether they have the requisite
experience, skillset and independence to truly represent YOUR best

In order to protect your investment and ensure that Senomyx remains on a
path of maximum value creation, we urge you to elect the seasoned and
experienced nominees put forth by your Company.

Let’s look at the facts when
comparing your Company’s nominees and the dissidents:

Your Board: Has articulated a clear strategic vision
for the future of Senomyx and is intensely focused on executing
initiatives to drive shareholder value.

  • Secured $275 million in development funding and is committed to
    securing additional non-dilutive funding for key program initiatives.
  • Focused on opportunities to collaborate on a non-exclusive basis with
    leading companies as part of a broader strategy to optimize the
    commercial potential of products from its Natural Sweet Program.
  • Recently secured $18 million in R&D funding from PepsiCo in order to
    advance the Company’s Natural Sweet Program, and is in discussions
    with approximately 20 companies to collaborate and secure additional
    R&D funding.
  • Senomyx has also focused on expense reductions and implemented a
    restructuring in December of 2016, resulting in an annualized savings
    of approximately $4 million.

    • The Company has narrowed the focus of its sweet taste R&D efforts
      to the Natural Sweet Program in response to market trends.

Your Board: Has demonstrated recent positive momentum
and financial results in line with current strategic initiatives.

  • Oversaw strong year-over-year growth in the fiscal year ended 2016 and
    continued strong results in 2017.

    • Commercial revenues were up 31% and delivered high gross margins
      at 88%.
    • Achieved continued direct sales revenue growth with Q1 2017 direct
      sales reaching more than double the previous highest-sales quarter
      since the Company began its initiative to extend its reach in the
  • Senomyx has demonstrated a history of discovering and advancing
    product candidates into the development phase.

    • Most recently, Senomyx advanced its lead natural high intensity
      sweetener, siratose, into the development phase.
  • While we don’t believe that the market fairly reflects the value of
    Senomyx stock, we are confident that our strategy will drive long-term
    value for shareholders.

Your Board: Has the right experience to provide
effective oversight at Senomyx and has adhered to principles of good
corporate governance.

  • Has necessary industry experience at companies in relevant sectors,
    including food and beverage, flavor and ingredient and pharmaceutical
    and life sciences.
  • Has an extensive history of director and executive leadership at both
    public and private companies in relevant industries.
  • Five Senomyx directors have served on the Board of Directors for
    publicly traded companies which have been acquired for over $1 billion
    in each sale.

Your Board: Is aligned with shareholders’ best

  • Owns over 673,000 shares (2.24%) of Senomyx, demonstrating alignment
    with and prioritization of the best interests of shareholders.
  • Has been transparent about strategic initiatives at Senomyx which are
    aligned with the best interests of all shareholders, to create lasting
    value at the Company.

The Dissidents: Have failed to articulate any sort of
plan and have already made repeated missteps.

  • With less than a month to go before the Annual Meeting, the dissident
    group has failed to share a strategic plan for the Company with
    shareholders. They have provided only a 215 word boiler plate
    statement that summarizes basic steps applicable to any company in any
  • Own a total of 300 shares of the Company, or less than 0.001%, all of
    which were recently purchased in December 2016 and January 2017. We
    believe this demonstrates an absence of long-term knowledge and true
    interest in the Company.
  • In the original nomination notices submitted to the Company by the
    dissidents, they sought to nominate 11 directors, when at that time
    the Board only had 8 seats, demonstrating a lack of elementary
    knowledge about the Company’s structure and current operations.
  • Never reached out to Senomyx prior to submitting their nominations,
    failing to offer the Company a chance to work with them constructively.
  • It is unclear why the dissidents are participating in this contested
    proxy contest to gain a change in control of Senomyx despite only
    owning 300 shares of stock.

The Dissidents: Lack relevant experience and
professional networks necessary to drive value at the Company.

  • While the dissident nominees claim that their public company board
    experience makes them well equipped to create value at Senomyx, they
    have not offered evidence that they actually have the relevant
    industry experience necessary to do so.
  • There is also no evidence of the dissident nominees possessing the
    necessary networks and relationships vital to creating future
    partnerships for product advancement and commercial success.

The Dissidents: Have had negative impacts on other
companies while serving on boards and lack independence from one
another, with several nominees having served on the same boards in the
Examples include:

  • Group member Charles Gillman, along with Barry Igdaloff and Robert
    Pearse, served together on the Novation Companies (OTC: NOVCQ) board,
    which ultimately filed for bankruptcy.1
  • Mark Stolper and David Pointer served together on the ALCO Stores
    (OTC: ALCSQ) board, which ultimately filed for bankruptcy.2
  • Lee Keddie, Benjamin Large and David Pointer served together on the
    CompuMed (OTC: CMPD) board, a company with a current market
    capitalization of less than $2.5 million with cash and cash
    equivalents of less than $100,000 for the quarter ending December 31,
    2016. 3
  • Lee Keddie and David Pointer were nominees on a dissident slate
    nominated by a fellow CSNS member in respect of the 2015 Annual
    Meeting of Shareholders of CUI Global, Inc. (NASDAQ: CUI).4
  • Lee Keddie, Charles Gillman, Barry A. Igdaloff and Benjamin E. Large
    are presently nominees on a dissident slate for election as directors
    at Birner Dental Management Services (OTC: BDMS).5


Senomyx’s current Board has a strategic plan in place, with positive
results that demonstrate that your Board is providing the necessary
oversight to ensure that initiatives are being executed and that the
Company is well positioned for future growth and success. It is critical
to avoid your Company being placed in the hands of a slate with
short-term interests and a lack of industry experience that is sure to
put your investment at risk. Vote on the WHITE
proxy card FOR all seven of the Company’s director nominees – Stephen A.
Block, Esq., Mary Ann Gray, Ph.D., Michael E. Herman, John Poyhonen,
Kent Snyder, Daniel E. Stebbins, and Christopher J. Twomey – at the
upcoming Annual Meeting.

Your vote matters and can ensure that Senomyx’s momentum is not arrested
at the expense of the dissidents’ short-term interests. We urge you to
allow your Board to continue to execute on our strategic plan with the
best interests of shareholders in mind.




The Board of Directors of Senomyx, Inc.

About Senomyx, Inc.

Senomyx discovers novel flavor
 and natural high intensity sweeteners that allow food
and beverage companies to create better-for-you products. Under its direct
 program, Senomyx sells its Complimyx® brand
flavor ingredients, Sweetmyx®Savorymyx®,
and Bittermyx®, to flavor companies for use in a
wide variety of foods and beverages. In addition, Senomyx has partnerships with
leading global food, beverage, and ingredient supply companies, which
are currently marketing products that contain Senomyx’s flavor
ingredients. For more information, please visit

If you have any questions or require any assistance with respect to
voting your shares, please contact the Company’s proxy solicitor at the
contact listed below:

470 West Avenue
Stamford, CT 06902
Call Toll Free: (800) 662-5200
Banks and Brokers Call Collect:
(203) 658-9400

Important Additional Information

Senomyx, its directors and certain of its executive officers will be
deemed to be participants in the solicitation of proxies from Company
shareholders in connection with the matters to be considered at the
Company’s annual meeting of shareholders scheduled to be held on May 11,
2017. The Company has filed a definitive proxy statement and a WHITE
proxy card with the U.S. Securities and Exchange Commission (the “SEC”)
in connection with its solicitation of proxies from Company
IMPORTANT INFORMATION. Information regarding the identity of
participants in this solicitation by the Company, and their direct or
indirect interests, by security holdings or otherwise, is set forth in
the proxy statement and other materials filed by the Company with the
SEC. Shareholders will be able to obtain the proxy statement, any
amendments or supplements to the proxy statement and other documents
filed by the Company with the SEC for no charge at the SEC’s website at
Copies will also be available for no charge at,
by writing to the Company at 4767 Nexus Centre Drive, San Diego,
California 92121 or by calling the Company’s proxy solicitor, Morrow
Sodali, at 1 (800) 662-5200.

Forward-Looking Statements

Information presented in this communication contains forward-looking
statements within the meaning of the Section 27A of the Securities Act
of 1933, as amended (the “Securities Act”), Section 21E of the
Securities Exchange Act of 1934 (the “Exchange Act”) and the Private
Securities Litigation Reform Act of 1995. All statements relating to
events or results that may occur in the future, including, but not
limited to, the development, growth and expansion of the Company’s
business, the Company’s intent, belief, or current expectations,
primarily with respect to the Company’s future operating performance,
and the product the Company expects to offer and other statements
regarding matters that are not historical facts, are forward-looking
statements. Forward-looking statements generally can be identified by
words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,”
“believe,” “continue,” or the negative of such terms, or other
comparable terminology. These statements are based on numerous
assumptions and involve known and unknown risks, uncertainties and other
factors that could significantly affect the Company’s operations and may
cause the Company’s actual actions, results, financial condition,
performance or achievements to be substantially different from any
future actions, results, financial condition, performance or
achievements expressed or implied by any such forward-looking
statements. Those factors include, but are not limited to, (i) general
economic and business conditions; (ii) changes in market conditions;
(iii) changes in regulations; (iv) actual or potential takeover or other
change-of-control threats; (v) the effect of merger or acquisition
activities; (vi) changes in the Company’s plans, strategies, targets,
objectives, expectations or intentions; and (vii) other risks,
uncertainties and factors indicated from time to time in the Company’s
reports and filings with the SEC including, without limitation, most
recently the Company’s Annual Report on Form 10-K for the period ended
December 31, 2016, under the heading Item 1A – “Risk Factors” and the
heading “Management’s Discussion and Analysis of Financial Condition and
Results of Operations.” The forward-looking statements speak only as of
the date on which they are made and the Company does not intend, and
undertakes no obligation to update or publicly release any revision to
any such forward-looking statements, whether as a result of the receipt
of new information, the occurrence of subsequent events, the change of
circumstance or otherwise, except as required by law. Each
forward-looking statement contained in the Company’s proxy statement is
specifically qualified in its entirety by the aforementioned factors.
You are advised to carefully read the Company’s proxy statement in
conjunction with the important disclaimers set forth above prior to
reaching any conclusions or making any investment decisions.




1 Charles Gillman, Barry Igdaloff and Robert Pearse served
together on the Novation Companies Inc. (OTC: NOVCQ) board. See the
4/29/16 Def14A:

2 Mark Stolper and David Pointer served together on the ALCO
Stores (OTC: ALCSQ) board. See the 8/29/14 Form 8-K:

3 Lee Keddie, Benjamin Large and David Pointer served
together on the CompuMed, Inc. (OTC: CMPD) board. See the 8/12/16
Quarterly Report:

4 Lee Keddie and David Pointer were nominees on a dissident
slate nominated by VCM in respect of the 2015 Annual Meeting of
Stockholders of CUI Global, Inc. (NASDAQ: CUI):

5 Lee Keddie, Charles Gillman, Barry A. Igdaloff and Benjamin
E. Large are presently nominees on a dissident slate for election as
directors at Birner Dental Management Services, Inc. (OTC: BDMS):

Click to comment


To Top